The evaluation of the avb6 integrin as a biomarkers and therapeutic target for idiopathic pulmonary fibrosis

Lead Research Organisation: University of Nottingham
Department Name: School of Life Sciences

Abstract

Idiopathic pulmonary fibrosis (IPF) is a disease where the fine, delicate structure of the lungs is replace by a hard, concrete-like substance called fibrous matrix. This prevents the normal functions of the lung, such as the transfer of oxygen from the air to the body, it also leads to irritation and persistent cough. The speed at which this concrete-like matrix is deposited in the lung varies between different people, but ultimately leads to death. Unfortunately it is difficult to predict who will get worse quickly, and who will get worse slowly. Furthermore, there are no treatments that can improve the outlook for people with IPF at the current time. The aim of this study is to develop a biological test that can predict which people with IPF are going to have slowly progressive disease compared with rapidly progressive disease. More importantly these biological tests will hopefully be able to be used to show whether a current, or new treatment, is working in an individual patient. This information will help patients plan their future when the receive a diagnosis of IPF and will help in the development of new treatments for this condition, which are so urgently sought.

Technical Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease of unknown aetiology. The pathogenesis of IPF is thought to be due to abnormal repair following alveolar epithelial injury within the lung. Current estimates suggest 4500 new cases of IPF each year in the UK, with median survival around 3 years. Furthermore, there has been a progressive increase in the incidence of IPF since the early 1980s. Considerable disease heterogeneity exists both in terms of clinical presentation and survival. However, there are no treatments that reduce the mortality or morbidity, although candidate treatments are emerging.
The aim of this proposal is to evaluate the alphavbeta6 integrin, which has an established role in the pathogenesis of fibrogenesis, as a potential biomarker in IPF. We will use immunohistochemistry from historical and prospective data sets as well as serum and lavage studies to evaluate alphavbeta6 integrin expression and downstream TGFbeta activation. We will develop a radiolabelled imaging strategy to permit real-time assessement of alphavbeta6 integrin expression which can then be followed longitudinally to assesss disease progression or response to therapy.
Specifically we aim to: 1) immunotype (alphavbeta6; alphaSMA, PAI-1, HGF) histological samples from patients undergoing surgical biopsies, to accurately determine patients with a poor prognosis compared with other fibrotic lung diseases; 2) develop non-invasive radioimaging (PET/CT and SPECT/CT) of pulmonary alphavbeta6 integrin levels to monitor the presence and progression of pulmonary fibrosis; 3) evaluate bronchoalveolar lavage and serum makers of alphavbeta6 integrin mediated TGFbeta activation in patients with IPF.
Initial studies will be performed in historical samples from patients with a diagnosis of lung fibrosis to determine whether . The cohort will be recruited within the established clinical network of centres in the whole Trent region, and will aim to recruit up to 225participants. At the time of diagnosis participants will be phenotyped in detail and the cohort will be followed for an average of 2.5 years (range 1 to 4 years). During this time we expect nearly 50% of our cohort to die. We will then determine which factors most accurately predict survival.
The results of this study will provide information regarding prognosis and disease progression in IPF. This information will be used to help plan the timing of therapeutic interventions such as lung transplantation as well as design of efficient clinical trials to alleviate the suffering of patients who suffer from this devastating disease.

Publications

10 25 50
 
Description Causal inference recommendations
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact Recommendations for interpretation of causal inference in observational studies published on behalf of all respiratory editors. Highly cited with big altimetric score in only a few months of publications
 
Description Chair of ATS workshop on pre-clinical models of fibrotic lung disease
Geographic Reach North America 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description ERS/ATS Clinical Guideline Committee for the Diagnosis of IPF
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Editor in Chief Thorax
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact As Editor-in-Chief of Thorax (the official journal of the British Thoracic Society and 4th highest Respiratory Journal) we have completely revised the instructions for authors to emphasise scientific rigour with explicit guidelines for research of many disciplines.
URL http://thorax.bmj.com/pages/authors/
 
Description MILD Fibrosis Meeting
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact No particular change in practice but dissemination of the information regarding the benefits of participating in Clinical Trials.
 
Description MILD Fibrosis meeting
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Wide ranging update to a range of health care practitioners regarding the diagnosis and treatment of IPF
 
Description NICE Nintedanib Scoping Workshop
Geographic Reach National 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description NICE PAS
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
Impact Pirfenidone is currently prescribed with under a patient access scheme for which my evidence formed part of the review.
 
Description Specialist Respiratory Clinical Reference Group
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Advising on reorganisation of Specialised Respiratory Services for NHS England
 
Description Workshop on the Future Directions of Pulmonary Fibrosis Research
Geographic Reach North America 
Policy Influence Type Participation in a national consultation
URL http://www.atsjournals.org/doi/abs/10.1164/rccm.201602-0254ST?url_ver=Z39.88-2003&rfr_id=ori:rid:cro...
 
Description Biogen Idec contract
Amount £200,000 (GBP)
Organisation Biogen Idec 
Sector Private
Country United States
Start 02/2014 
End 01/2016
 
Description Clinical Fellowship
Amount £279,483 (GBP)
Funding ID MR/P001327/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2016 
End 10/2019
 
Description DEMISTIFI Multi Morbidity: DEfining MechanIsms Shared across mulTI-organ FIbrotic disease to prevent the development of long term multi-morbidity
Amount £100,810 (GBP)
Funding ID MR/V005324/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2020 
End 01/2021
 
Description Developing a biomarker guided strategy to treat patients with pulmonary fibrosis
Amount £1,700,000 (GBP)
Funding ID NIHR-RP-2017-08-ST2-014 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 12/2018 
End 11/2023
 
Description Development of inhaled, dual EP2/4 receptor agonists for the treatment of idiopathic pulmonary fibrosis
Amount £1,592,770 (GBP)
Funding ID MR/V005928/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2021 
End 08/2023
 
Description Large Project Award
Amount £464,413 (GBP)
Funding ID N/A 
Organisation Barts Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 12/2020
 
Description MICA: Defining Endotypes of Pulmonary Fibrosis by Understanding the Functional Consequences of Known, and Novel, Genetic Associations with Disease
Amount £2,045,605 (GBP)
Funding ID MR/V00235X/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2021 
End 05/2026
 
Description MRC Case Award
Amount £100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2016 
End 09/2020
 
Description Medical Research Foundation Respiratory Disease Call
Amount £250,000 (GBP)
Organisation Medical Research Council (MRC) 
Department Medical Research Foundation
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 06/2019
 
Description Medical Research Foundation Respiratory Disease Call
Amount £250,000 (GBP)
Organisation Medical Research Council (MRC) 
Department Medical Research Foundation
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 09/2019
 
Description Molecular Pathology Node
Amount £2,400,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2015 
End 09/2020
 
Description Project Award
Amount £179,982 (GBP)
Funding ID N/A 
Organisation Pancreatic Cancer Research Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 09/2019
 
Description Refining Radiation Models of Fibrosis
Amount £48,000 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 03/2014 
End 03/2016
 
Description Research Grant G1100564
Amount £553,341 (GBP)
Funding ID G1100564/1 
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Public
Country United Kingdom
Start 09/2011 
End 04/2015
 
Description The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID.
Amount £2,014,983 (GBP)
Funding ID MR/W006111/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 02/2021 
End 08/2022
 
Description The role of G protein regulated TGF+ generation in airway smoothmuscle cells in Asthma
Amount £98,652 (GBP)
Funding ID AUK-PHD-2016-380 
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 02/2020
 
Description Understanding the role of infection & extracellular matrix in idiopathic pulmonary fibrosis using stem cell derived alveolar cells. PI Nick Hannan MR/S009930/1
Amount £728,625 (GBP)
Funding ID MR/S009930/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2019 
End 08/2022
 
Description Using organoids to understand how akap13 regulates integrin-mediated mechanotransduction signalling to promote pulmonary fibrosis
Amount € 154,000 (EUR)
Funding ID R3201712-00251 
Organisation European Respiratory Society (ERS) 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2018 
End 06/2019
 
Title Beta6 integrin imaging 
Description We can now perform whole lung imaging of avb6 integrin expression 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact This technology is being used by us for commercial groups and would be made available to other groups if requested. Studies are ongoing to translate it into a clinical tool. 
 
Title Biological samples from patients with IPF 
Description We have begun collecting blood and lavage from patients with IPF. Some will be stored for sharing after primary analysis 
Type Of Material Biological samples 
Provided To Others? No  
Impact These biological samples are at an early stage of collection and therefore no impcts have resulted as yet. 
 
Title Lung specific G protein null mouse 
Description As part of the program to assess integrin mediated TGFbeta activity in mice we have developed a lung epithelial specific Gq/11 double and G12/13 double knockout mouse. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact These mice are currently being characterised and no notable impacts have yet been reported. 
 
Title Myofibroblast TGF-ß Activation Measurement In Vitro. 
Description Book chapter describing assays to measure TGFbeta activation in myofibroblasts. 
Type Of Material Technology assay or reagent 
Year Produced 2021 
Provided To Others? Yes  
Impact These assays are widely used in our studies and we hope this chapter will facilitate the performance of TGFbeta assays appropriately in other studies. 
 
Title PROFILE Study database 
Description We have a collection of over 330 biological samples with matched clinical data from patients with incident IPF 
Type Of Material Database/Collection of data 
Year Produced 2013 
Provided To Others? Yes  
Impact First paper is under review at Lancet and further papers are planned. A number of lectures describing the PROFILE cohort have been delivered and two articles have cited the development of the PROFILE cohort. 
 
Description DEMISTIFI Consortium 
Organisation AstraZeneca
Department MedImmune
Country United Kingdom 
Sector Private 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation Genentech, Inc
Country United States 
Sector Private 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description DEMISTIFI Consortium 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution I established the development of a multi-organ fibrosis consortium to try and prevent the development of multi morbidity.
Collaborator Contribution There are a number of partners involved in this consortium including genetic epidemiologist, MRI physicists, clinicians, fundamental biologists and data scientists as well as patient public representatives and also industry partners. These partners bring a wealth of expertise and resources to the collaboration.
Impact DEMISTIFI collaboration bid submitted.
Start Year 2020
 
Description MedImmune MRC-CASE awards 
Organisation AstraZeneca
Department MedImmune
Country United Kingdom 
Sector Private 
PI Contribution I am supervising a PhD with input from MedImmune having successfully submitted an MRC CASE award.
Collaborator Contribution MedImmune will be co-supervising the award.
Impact None yet
Start Year 2015
 
Description Nottingham Molecular Pathology Node 
Organisation Galecto Biotech
Country Sweden 
Sector Private 
PI Contribution I am supervising a PhD jointly funded by the MRC and Galecto Biotec
Collaborator Contribution Galecto part funding the PhD
Impact None yet
Start Year 2015
 
Description UK Interstitial Lung Disease Consortium 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University of Cambridge
Department Department of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University of Hull
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University of Leicester
Department Genetic Epidemiology
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Description UK Interstitial Lung Disease Consortium 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis
Collaborator Contribution Provided patient samples and data Provided data analysis Undertook genotyping
Impact Data analysis still ongoing
Start Year 2012
 
Title Humanised PET Ligand 
Description This is a methodology study to examine the quantification of GSK2634673F binding in humans, with the aim of characterising a robust, non-invasive method to quantify the specific binding signal for the alpha(V)beta6 protein in human tissues. This will be the first time that this micro-dose ligand is administered to humans. The study will consist of three parts; Part A, Part B and Part C. Healthy subjects will be recruited into Parts A and B of the study in order to gain experience with the GSK2634673F positron emission tomography (PET) ligand and to optimise the scanning procedures prior to administration to IPF patients in Part C. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
Impact This study will identify whether the avb6 integrin can be used as a PD biomarker for interventional clinical trials. 
URL https://clinicaltrials.gov/ct2/show/NCT02052297
 
Title Nordic Biomarkers 
Description The Nordic biomarkers that we identified in our Lancet paper Jenkins et al 2015, are now been assessed as theranostic biomarkers in an interventional clinical trial sponsored by Boehringer Ingelheim. NCT02788474 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2016
Development Status Under active development/distribution
Impact These biomarkers are now being assessed in a large number of interventional clinic trials. 
URL https://clinicaltrials.gov/ct2/show/NCT02788474
 
Description Aegean Conference 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote Lecture at WASOG Meeting in Crete 2018
Year(s) Of Engagement Activity 2018
 
Description American Thoracic Society Talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact Talk sparked questions and discussions afterwards

International collaborations developed
Year(s) Of Engagement Activity 2013
 
Description Argentinian Respiratory Society, Buenos Aires, Argentina 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a talk entitled: "Dangerous relationships: COVID-19 and pulmonary fibrosis" to clinicians in Argentina via zoom.
Year(s) Of Engagement Activity 2021
 
Description BSA Public Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Deliver British Science Week public lecture to British Science Association
Year(s) Of Engagement Activity 2018
URL http://nottsbsa.org/calendar/public-lecture-can-breathing-scar-lungs/
 
Description British Association of Lung Research meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Gave a talk entitled pulmonary Fibrosis and the effect of SARS-CoV2 on the alveolar epithelium
Year(s) Of Engagement Activity 2020
 
Description British Association of Lung Research, Cambridge, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Gave a keynote talk to a range of students and scientists about my work understanding how epithelial injury leads to failed repair and pulmonary fibrosis.
Year(s) Of Engagement Activity 2019
URL http://anaesthetics.medschl.cam.ac.uk/ccg/british-association-of-lung-research-2019-meeting/
 
Description British Inflammation Research Association 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Talked sparked discussion afterwards

Networking opportunites
Year(s) Of Engagement Activity 2014
 
Description British Thoracic Society meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Talk at the online British Thoracic Society summer meeting which is the premier educational conference for respiratory practitioners in UK. Lots of questions and requests for further engagement activities.
Year(s) Of Engagement Activity 2021
 
Description CRUK Supporters Visit Feb 2017 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact To update CRUK supporters on my research.
Year(s) Of Engagement Activity 2017
 
Description Cambridge Respiratory Research Seminars, University of Cambridge, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Talk entitled Understanding Pulmonary Fibrosis in the Post COVID World
Year(s) Of Engagement Activity 2021
 
Description Cambridge respiratory Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Talk sparked discussion

Collaborative opportunnities
Year(s) Of Engagement Activity 2013
 
Description Cardiorespiratory Interface Section Seminar, Imperial College London,UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact Online seminar entitled: Priming the alveolus: do your genes and the environment matter in Acute Lung Injury? Lots of questions asked.
Year(s) Of Engagement Activity 2021
 
Description Daily Mail interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Daily Mail interview on IPF and the risk factors associated with it.
Year(s) Of Engagement Activity 2019
URL https://www.dailymail.co.uk/news/article-6797279/Thousands-victims-suffering-fatal-lung-condition-le...
 
Description Discovery Medicine Clinical Insight Session, GlaxoSmithKline 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact Provided a zoom lecture to GSK about how the learnings from COVID19 may inform future studies in IPF entitled "What can the COVID-19 pandemic teach us about Idiopathic Pulmonary Fibrosis?" Lots of positive feedback and questions asked.
Year(s) Of Engagement Activity 2022
 
Description ERS COVID special meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a 15 minute talk on epithelial response to viral infection and panel discussion on ALI post COVID.
Year(s) Of Engagement Activity 2020
 
Description ERS Satellite Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talk entitled horizon scanning in ILD aimed at considering the future management of ILD.
Year(s) Of Engagement Activity 2021
 
Description ERS Satellite meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact ERS Satellite meeting. Online multi-centre meeting across Europe.
Year(s) Of Engagement Activity 2019
URL https://www.ersnet.org/congress-and-events/ers-satellite
 
Description European Pulmonary Fibrosis Summit, Europe 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Patients, carers and/or patient groups
Results and Impact Plenary Lecture "The joint challenges of Covid 19 & Curing the Incurable" at the major patients engagement conference in Europe
Year(s) Of Engagement Activity 2021
URL https://www.eu-ipff.org/european-pf-patient-summit-2021
 
Description European Respiratory Society, meeting Munich, Germany. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a talk entitled "Biomarker discovery, development, and implementation in interstitial lung disease" to the European Respiratory Society annual meeting via zoom.
Year(s) Of Engagement Activity 2021
 
Description Fibrosis Conference (Rhodes) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 90 researchers from across organ systems and across the world attended the conference and my talk sparked discussion and debate afterwards.
Year(s) Of Engagement Activity 2016
URL http://www.aegeanconferences.org/src/App/conferences/view/112
 
Description Gordon Research Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact KEYNOT TALK AT THE GORDON RESEARCH SEMINAR AND CONFERENCE
Year(s) Of Engagement Activity 2017
 
Description Gordon Research Conference one Alveolar Repair and Regeneration 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a talk entitled "Alveolar Injury and the Development of Post COVID Fibrosis." which lead to considerable engagement and a new collaboration.
Year(s) Of Engagement Activity 2021
 
Description Grand Round, University of Sao Paulo Medical School 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a talk to Brazilian pulmonologists entitled Three Steps to Curing Idiopathic Pulmonary Fibrosis
Year(s) Of Engagement Activity 2020
 
Description Guardian Supplement 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Guardian Respiratory Health supplement
Year(s) Of Engagement Activity 2018
URL https://issuu.com/mediaplanetuk/docs/respiratory_health_2018
 
Description ICLAF 2014 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact Talk sparked discussion

Numerous collaborative requests and possible review
Year(s) Of Engagement Activity 2014
 
Description ICLAF2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote lecture at the International Colloquium of Lung and Airway Fibrosis
Year(s) Of Engagement Activity 2018
URL http://www.iclaf.org
 
Description IPF Summit 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Talk entitled Mechanisms of COVID-19 induced alveolar injury and fibrogenesis
Year(s) Of Engagement Activity 2020
 
Description KUCI meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Annual Kings College London, University College London and Imperial College London (KUCI) Respiratory Society meeting Brockenhurst, UK.
Year(s) Of Engagement Activity 2021
 
Description Keynote lecture at the Japanese Respiratory Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I gave a keynote address to about an audience of about 100 in Tokyo in Japan
Year(s) Of Engagement Activity 2019
URL https://www.jrs.or.jp/modules/english/index.php?content_id=27
 
Description Lecture at the Royal Brompton Hospital 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Will COVID-19 lead to a surge of Interstitial Lung Disease and how should we manage it?
Year(s) Of Engagement Activity 2020
 
Description London Matrix Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Talk sparked discussion

Collaborative requests
Year(s) Of Engagement Activity 2013
 
Description Max-Plank Retreat, Geissen, Germany 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Was a faculty member at the Max-Plank Retreat, Geissen, Germany where I gave a lecture and facilitate a number of workshops aimed at helping post doctoral fellows in the future career.
Year(s) Of Engagement Activity 2019
 
Description Meeting in Holland 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave talk at a multidisciplinary meeting held every 5 years on the topic Early Detection of Chronic Lung Disease: Biomarkers, Imaging and Beyond.
Year(s) Of Engagement Activity 2019
URL https://www.nrs-science.nl/news/bronchitis-x-symposium-19-21-june-2019-in-groningen/
 
Description Middlesborough Support Group Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Visited support group for patients with IPF in Middlesbrough to discuss their condition.
Year(s) Of Engagement Activity 2018
 
Description Munich International Autumn School 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Large international meeting to the largest Respiratory Research group in Germany that also attracted an audience from access Europe and the world, I delivered two lectures and participated in group workshops with a number of post docs.
Year(s) Of Engagement Activity 2015
URL https://www.helmholtz-muenchen.de/en/press-media/press-releases/.../index.html
 
Description Munich Lung Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote speaker at the Munich Lugn Conference 13-14 April 2018
Year(s) Of Engagement Activity 2018
URL https://mlc2018.helmholtz-muenchen.de
 
Description NIHR UK Clinical Research Facility conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact I gave a lecture to the NIHR UK CRF which generated a number of discussions and a short video was made of an interview with the local NIHR comms team afterwards
Year(s) Of Engagement Activity 2019
 
Description Nordic Respiratory Society meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact Talk sparked questions and discussions afterwards

International contacts developed
Year(s) Of Engagement Activity 2013
 
Description Patient Day 2013 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact 100 patients and carers attended, sparking discussion.

Formation of the national IPF Charity Action of Pulmonary Fibrosis
Year(s) Of Engagement Activity 2012,2013
URL http://www.actionpulmonaryfibrosis.org/
 
Description Patient Priority Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact 110 patients or patient relatives attended a one day conference informing them about their disease (IPF)

Formation of Pulmonary Fibrosis Association Patient Group
Year(s) Of Engagement Activity 2012
 
Description Portugese Respiratory Society Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a talk on ILD and fibrosis following SARS-COV-2 infection
Year(s) Of Engagement Activity 2020
 
Description Pulmonary and Critical Care Grand Rounds, University of Birmingham Alabama. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Visiting Professor (via Zoom) at the University of Birmingham, Alabama, USA and had a series of one to one meetings with potential collaborators and gave lecture at the the Univesirty of Alabama Ground Rounds.
Year(s) Of Engagement Activity 2021
 
Description Pulmonology Excellence ILD@Royal Brompton Hospital, Italy 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Educational workshop hosted by the Interstitial Lung Disease Unit at the Royal Brompton Hospital for Italian physicians. I gave talk entitled "Current translational research in lung fibrosis."
Year(s) Of Engagement Activity 2021
 
Description Qatar Genome project visit 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Had a visit to Qatar to discuss genomics and genetics of interstitial lung disease.
Year(s) Of Engagement Activity 2019
 
Description Respiratory Drug Delivery Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Title entitled "Mechanisms of Alveolar Injury and Fibrogenesis: Developing Stratified Approaches for Pulmonary Fibrosis Treatment"
Year(s) Of Engagement Activity 2021
 
Description Roche European Respiratory Society virtual evening symposium  
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave a presentation entitled: The Changing IPF Treatment Landscape: Working For A Better Future for Patients with IPF.
Year(s) Of Engagement Activity 2021
 
Description Royal College of Physicians Advanced Medicine Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact talk sparked discussion afterwards

Talk lead to an invited review
Year(s) Of Engagement Activity 2014
 
Description Royal College of Physicians Update 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Approximately 200 physicians around the west midlands attended and I had discussions about the diagnosis and management of pulmonary fibrosis subsequently
Year(s) Of Engagement Activity 2016
URL https://www.rcplondon.ac.uk/events/regional-update-medicine-west-midlands
 
Description Royal College of Physicians and Surgeons Glasgow 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Talk sparked discussions afterwards

After my talk slides were requested
Year(s) Of Engagement Activity 2013
 
Description Seminar at Imperial College London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Understanding Integrin Biology in the Lung: From Covid-19 to Idiopathic Pulmonary Fibrosis
Year(s) Of Engagement Activity 2020
 
Description Summer BALR meeting in 2013 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact Me and my team organised a two day scientific meeting and accompanying Patient Support day in July 2013. The feedback from the days was outstanding, there was a huge amount of discussion and the attendance at the conference was a record.

Increased collaborations, videos of patient day posted on the pulmonary fibrosis foundation website.
Year(s) Of Engagement Activity 2013
URL http://www.pulmonaryfibrosis.org/life-with-pf/pff-educational-resources/webinars
 
Description Talk at Kings Health Partners and Royal Brompton Hospital 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Talk entitled Acute lung inflammation COVID-19: From Bench to Bedside and Beyond - Planning for the 2nd Wave.
Year(s) Of Engagement Activity 2020
 
Description The Annual Margaret Turner Warwick Lecture and Inaugural Lecture for the MTW Centre for Fibrosing Lung Diseases, Imperial College, London, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Annual lecture entitled: curing the incurable.
Year(s) Of Engagement Activity 2021
URL https://www.youtube.com/watch?v=K6rgn8P_1fI
 
Description Thoracic Society of Australia and New Zealand Annual Congress 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I was invited to give a number of educational and scientific and keynote talks at the TZANZ in raw Gold Coast Australia.
Year(s) Of Engagement Activity 2019
URL http://www.tsanzsrs2019.com/program/
 
Description Tissue Fibrosis: State-of-the-Art 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Widespread discussions of future collaboration

Tissue Fibrosis Website to be generated
Year(s) Of Engagement Activity 2014
 
Description UCD Visiting Professor 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Visting professor at UCD
Year(s) Of Engagement Activity 2017
 
Description Virtual visit to Cincinnati Children's Hospital USA 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Group visits and seminar entitled the importance of Integrins in fibrogenesis: from COVID-19 to Pulmonary Fibrosis.
Year(s) Of Engagement Activity 2020
 
Description Visit to Centro Studi Società Italiana di Pneumologia in Rome 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact About 75 doctors and clinical fellows attended to discuss patient management, journal publications and research in interstitial lung disease.
Year(s) Of Engagement Activity 2019
 
Description Visiting Prof at Cedars Sinai 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Visiting Professor at Ceders Sinai LA
Year(s) Of Engagement Activity 2018
 
Description WASOG Crete 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote presentation at the World Association of Granulomatous Diseases 2018
Year(s) Of Engagement Activity 2018
 
Description Webinar at St Joesph's Hospital, Hamilton, Canada 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The importance of Integrins in fibrogenesis: from COVID-19 to Idiopathic Pulmonary Fibrosis.
Year(s) Of Engagement Activity 2020
 
Description World Association of Sarcoidosis and other Granulomatous Disease 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was an international multidisciplinary meeting about the diagnosis and treatment of sarcoid and other granulomatous diseases involving patient groups, scientists and clinicians.
Year(s) Of Engagement Activity 2019
URL http://wasog2019.jp
 
Description Wright-Fleming Institute Infection and Immunity seminar St Mary's Hospital Imperial College London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact Gave a talk via Teams to researchers entitled 'Understanding Pulmonary Fibrosis in the Post COVID World.' lots of questions and requests for face to face follow-up visits.
Year(s) Of Engagement Activity 2022
 
Description Y12 NHLI Work Experience: Research of Interstitial lung disease & pulmonary fibrosis 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Gave a lecture to sixth form students about how and why we go about trying to cure an incurable disease. Received a lot of questions and it stimulated a lot of debate.
Year(s) Of Engagement Activity 2021